• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gynaecological oncology >Diagnosis and treatment of borderline ovarian neoplasms 'the state of the art'.
【24h】

Diagnosis and treatment of borderline ovarian neoplasms 'the state of the art'.

机译：交界性卵巢肿瘤的诊断和治疗是“最新技术”。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The 5-year survival for women with Stage-I borderline tumours (BOT) is favourable, about 95-97%, but the 10-year survival is only between 70 and 95%, caused by late recurrence. The 5-year survival for Stage II-III patients is 65-87%. Standard primary surgery includes bilateral SOEB, omentectomy, peritoneal washing and multiple biopsies. Second cytoreductive surgery is recommended for patients with recurrent disease. Adjuvant postoperative therapy is not indicated in Stage-I diploid tumors. Occasional responses to chemotherapy have been reported in advanced BOTs but no study has shown improved survival. Recently a new theory has been developed describing a subset of S-ovarian cyst adenomas that evolve through S-BOT to low-grade carcinoma. A more correct staging procedure, classification of true serous implants and agreement on the contribution to stage of the presence of gelatinous ascites in mucinous tumours may in the future change the distribution of stage and survival data by stage for women with BOT. Independent prognostic factors in patients with epithelial ovarian BOT without residual tumour after primary surgery are DNA-ploidy, international FIGO-stage, histologic type and patient age. Studies on other molecular markers have not yet uncovered a reliable prediction of biologic behaviour, however, there is hope that future studies of genetics and molecular biology of these tumours will lead to useful laboratory tests. Future questions to be addressed in this review include the following: Have patients with borderline tumours in general been over-treated and how should these patients be treated? How to define the high-risk patients? In which group of patients is fertility-sparing surgery advisable and, do patients with borderline tumours benefit from adjuvant treatment?
机译：患有I期边缘性肿瘤（BOT）的女性的5年生存率较高，约为95-97％，但由于晚期复发，其10年生存率仅在70％至95％之间。 II-III期患者的5年生存率为65-87％。标准的主要手术包括双侧SOEB，网膜切除术，腹膜冲洗和多次活检。对于复发性疾病患者，建议进行第二次细胞减灭术。在I期二倍体肿瘤中未指示术后辅助治疗。在晚期BOT中已报道了对化学疗法的偶尔反应，但尚无研究显示存活率提高。最近，已经开发出一种新理论来描述通过S-BOT演变为低度癌的S-卵巢囊肿腺瘤的一个子集。今后，更正确的分期程序，真正的浆液植入物的分类以及关于粘液性肿瘤中胶状腹水存在的阶段性贡献的协议可能会在将来改变BOT妇女的阶段性和生存数据分布。初次手术后没有残留肿瘤的上皮性卵巢BOT患者的独立预后因素是DNA倍性，国际FIGO分期，组织学类型和患者年龄。关于其他分子标记的研究尚未发现生物学行为的可靠预测，但是，人们希望这些肿瘤的遗传学和分子生物学的进一步研究能够导致有用的实验室检查。这篇综述中将要解决的未来问题包括：一般而言，边缘性肿瘤患者是否接受过治疗，应如何治疗？如何定义高危患者？在哪一组患者中建议保留生育能力的手术？患有边缘肿瘤的患者是否可以从辅助治疗中受益？

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号